Clinical Trials Browser

Interventional × Adenocarcinoma × zolbetuximab × Clear all

NCT06901531 2026-03-11

LUCERNA

Phase 3 Recruiting

Adenocarcinoma, Neoplasms

NCT07431281 2026-02-24

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03504397 2026-02-13

Spotlight

Phase 3 Active not recruiting

565 enrolled 63 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03653507 2026-02-06

GLOW

Phase 3 Active not recruiting

507 enrolled 65 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04086758 2024-11-20

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Phase 1 Completed

Adenocarcinoma